Psoriasis is a persistent, chronic autoimmune skin disease that affects around 2% of the global population. Conventional therapies often exhibit limited efficacy, systemic side effects, and poor patient compliance due to long-term treatment needs. This study focused to develop and optimize a sulfasalazine-loaded microemulsion (SSZ-ME) for topical delivery to enhance skin penetration and therapeutic efficacy in psoriasis. Pseudo-ternary phase diagrams were prepared to identify the optimal surfactant mixture, with Tween 80 and Polyethylene Glycol 400 selected in a 2:1 ratio. A 23 factorial design was used to optimize formulation parameters, focusing on oil and surfactant mixture effects on globule size and viscosity. The resulting microemulsions showed globule sizes between 60 ± 0.42 to 349 ± 0.13 nm, with optimal viscosity. In vitro release studies confirmed sustained drug release over 24 hours, following first-order kinetics. Skin permeation studies demonstrated enhanced drug penetration with SSZ-ME, while histopathological analysis revealed significant improvements in psoriatic symptoms in mice treated with 4% SSZ-ME compared to 2% SSZ-ME and marketed formulation. Blood analysis confirmed minimal systemic absorption and localized action. These results suggest that SSZ-ME offers a promising, patient-compliant, and effective topical therapy for psoriasis with improved therapeutic outcomes and minimal systemic exposure.
13 August 2026 in Journal of Pharmaceutical Technology, Research and Management
Background: Globally, colorectal cancer represents one of the most common types of cancer, along with being one of the top 10 causes of cancer-related deaths. Epidermal Growth Factor Receptors (EGFRs) are a major target for colorectal cancer, and quinazoline derivatives have shown anticancer activity as EGFR inhibitors. Purpose: The objective of this research was the development of a two-dimensional quantitative structure–activity relationship model (2D-QSAR); that is, to develop a simple way to identify the structural components that help predict a potent compound with the highest predicted activity among the series of quinazoline derivatives for EGFR inhibitors for colorectal cancer. Methods: A dataset of 21 quinazoline derivatives was collected from the literature, molecular descriptors were calculated, and Partial Least Squares (PLS) regression was used to develop statistically significant QSAR models. Generated and validated using internal and external validation parameters. Results: Model-1 (RANDOM_70_30_SFB_PLS_TRIALS_2) showed the best statistical performance with r² = 0.6538, q² = 0.5314, pred-r² = 0.6940, and an F-test value of 22.6638. The descriptors SsssNcount and SaaCHE-index were identified as significant contributors to EGFR inhibitory activity, indicating that tertiary nitrogen count and charge distribution play crucial roles in determining biological potency. Conclusion: The developed 2D-QSAR model identified a potent compound with the highest predicted biological activity as an EGFR inhibitor for colorectal cancer.
Introduction: FAK and PLK1 are regulators of oncogenic signaling and metastasis, and their coinhibition offers a synergistic anticancer strategy. This study employed computational modeling to design quinazoline-based scaffolds as potential dual FAK–PLK1 inhibitors. Methods: 54 quinazoline derivatives were analyzed using 2D/3D-QSAR, pharmacophore mapping, pharmacokinetic (ADMET) profile prediction, and molecular docking (PyRx–AutoDock Vina) to identify structural features and evaluate their dual FAK–PLK1 inhibitory potential with favourable pharmacokinetics properties. Results: 2D-QSAR modeling of 54 quinazoline derivatives yielded statistically significant models, with Model 2 exhibiting the best performance (r² = 0.6504, q² = 0.5704, Pred_r² = 0.5360, F = 31.63). The 3DQSAR kNN-MFA analysis produced a reasonably reliable predictive model (q² = 0.6970, Pred_r² = 0.6528), confirming the contribution of steric and electrostatic fields to dual FAK–PLK1 inhibition. ADMET predictions supported favourable pharmacokinetic and safety profiles for compounds 28 and 33. Molecular docking revealed that compounds 28 and 33 displayed the highest binding affinities toward FAK and PLK1, outperforming reference inhibitors PF-573228 and BI 2536. RMSD values (1.18–2.31 Å) indicated stable ligand conformations. Discussion: The 2D- and 3D-QSAR models showed strong predictive ability, confirming the role of steric and electrostatic factors in dual FAK–PLK1 inhibition. Docking and ADMET analyses identified compounds 28 and 33 as potent, stable, and pharmacokinetically favourable dual inhibitors. Conclusion: This integrated computational approach combining QSAR modeling, pharmacophore analysis, ADMET prediction, and molecular docking identified promising quinazoline scaffolds as potential dual FAK–PLK1 inhibitors for the treatment of metastatic cancers, such as breast, colon, and non-small cell lung cancer.
31 July 2026 in Journal of Applied Pharmaceutical Research
Background: Thrombocytopenia is a hematological disorder characterized by a reduced platelet count, increasing the risk of bleeding and impairing hemostasis. The present study aimed to develop and optimize a fixed-dose combination tablet comprising a sirolimus nanodispersion layered onto a prednisolone core tablet using a Box–Behnken experimental design as a potential therapeutic strategy for thrombocytopenia. Methodology: Sirolimus nanodispersion drug-layered tablets were prepared and optimized using a three-factor, three-level Box–Behnken design. The optimized formulation was evaluated for critical quality attributes, including hardness and friability, and subsequently experimentally validated. Therapeutic efficacy was investigated in cyclophosphamide-induced thrombocytopenic Wistar rats by assessing platelet count, bleeding time, clotting time, and hematological parameters, including red blood cell count, hemoglobin, and hematocrit. Results and Discussion: The optimized formulation exhibited acceptable mechanical properties, with hardness ranging from 5.3 to 5.5 kg/cm² and friability below 1%, confirming the robustness of the optimization process. In vivo evaluation demonstrated a marked improvement in platelet recovery following treatment. The platelet count increased from 39.87 ± 8.82 × 10³/mm³ in the disease control group to 132.62 ± 21.76 × 10³/mm³ and 154.57 ± 7.40 × 10³/mm³ after once-daily and twice-daily administration, respectively. Furthermore, treatment significantly improved bleeding time, clotting time, and hematological parameters, indicating enhanced therapeutic efficacy. Conclusion: The optimized sirolimus nanodispersion drug-layered prednisolone tablet demonstrated favorable pharmaceutical characteristics and significant therapeutic efficacy in the cyclophosphamide-induced thrombocytopenia model. The developed fixed-dose combination represents a promising formulation strategy for improving the management of thrombocytopenia and warrants further preclinical and clinical investigation.
22 September 2026 in Journal of Pharmaceutical Innovation